Immune Responses in the Glaucomatous Retina: Regulation and Dynamics
Valery I Shestopalov1,2,3,4, Markus Spurlock2,3, Oliver W Gramlich5,6,7
1Department of Ophthalmology, Miller School of Medicine, University of Miami, Miami, FL 33101, USA.
Abstract:
Glaucoma is a multifactorial disease resulting in progressive vision loss due to retinal ganglion cell (RGC) dysfunction and death. Early events in the pathobiology of the disease include oxidative, metabolic, or mechanical stress that acts upon RGC, causing these to rapidly release danger signals, including extracellular ATP, resulting in micro- and macroglial activation and neuroinflammation. Danger signaling also leads to the formation of inflammasomes in the retina that enable maturation of proinflammatory cytokines such IL-1β and IL-18. Chronic neuroinflammation can have directly damaging effects on RGC, but it also creates a proinflammatory environment and compromises the immune privilege of the retina. In particular, continuous synthesis of proinflammatory mediators such as TNFα, IL-1β, and anaphylatoxins weakens the blood-retina barrier and recruits or activates T-cells. Recent data have demonstrated that adaptive immune responses strongly exacerbate RGC loss in animal models of the disease as T-cells appear to target heat shock proteins displayed on the surface of stressed RGC to cause their apoptotic death. It is possible that dysregulation of these immune responses contributes to the continued loss of RGC in some patients.
Insights
Glaucoma causes vision loss through retinal ganglion cell (RGC) death. Neuroinflammation and immune responses, involving cytokines and T-cells, exacerbate RGC damage, potentially contributing to disease progression.
Area of Science:
- Ophthalmology
- Neuroscience
- Immunology
Background:
- Glaucoma is a leading cause of irreversible blindness.
- Retinal ganglion cell (RGC) dysfunction and death are hallmarks of glaucoma.
- Early disease stages involve cellular stress, danger signaling, and neuroinflammation.
Purpose of the Study:
- To elucidate the role of neuroinflammation and immune responses in glaucoma pathogenesis.
- To investigate the mechanisms by which immune cells contribute to RGC loss.
Main Methods:
- Analysis of danger signaling pathways in response to cellular stress.
- Investigation of inflammasome activation and cytokine production in the retina.
- Assessment of adaptive immune responses, including T-cell involvement, in glaucoma models.
Main Results:
- Extracellular ATP release triggers micro- and macroglial activation, leading to neuroinflammation.
- Inflammasomes mature proinflammatory cytokines (e.g., IL-1β, IL-18).
- Adaptive immunity, particularly T-cells targeting stressed RGCs, exacerbates RGC death.
Conclusions:
- Chronic neuroinflammation compromises retinal immune privilege and damages RGCs.
- Dysregulated immune responses, including T-cell activity, significantly contribute to RGC loss in glaucoma.
- Targeting inflammatory pathways may offer therapeutic strategies for glaucoma.
Related Concept Videos
01:25Glaucoma: Overview
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:20Anatomy of the Eyeball
01:28Angle Closure Glaucoma: Treatment